<DOC>
	<DOCNO>NCT02787070</DOCNO>
	<brief_summary>Plasmodium vivax form dormant liver stage reactivate week month follow acute infection . Recurrent infection associate febrile illness , cumulative risk severe anaemia , even mortality . In co-endemic area risk recurrence P. vivax P. falciparum infection 50 % within 3 month . The drug kill P. vivax hypnozoites primaquine currently give 14 day regimen . In Papua retrospective study find low effectiveness unsupervised treatment . If true profound effect treatment policy , suggest great effort need encourage adherence treatment . We propose cluster randomize , control , open label trial ass effectiveness unsupervised versus supervise primaquine treatment patient uncomplicated malaria . Since risk recurrent P. vivax high patient either P. vivax P. falciparum , infection include study . The study conduct Mimika , southern part Papua Province , Indonesia . Participants enrol village health post provide schizontocidal treatment plus primaquine radical cure either supervise unsupervised depend cluster clinic . Participants follow 6 month assess regular interval presence patent sub-patent malaria . The outcome study contribute improve treatment scheme uncomplicated malaria area .</brief_summary>
	<brief_title>A Randomized Controlled Trial Malaria Primaquine Treatment Timika , Indonesia ( TRIPI )</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<criteria>Infection Plasmodium falciparum P. vivax either alone mixed Age &gt; 12 month Weight &gt; 5kg Living study cluster General danger sign symptom severe malaria Anaemia , define Hb &lt; 9g/dl G6PD deficiency ( determined FST ) Pregnant woman determine Urine Î²HCG pregnancy test Known hypersensitivity drug give</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>